How to Provide the Needed Protection from COVID-19 to Patients with Hematologic Malignancies

Patients with hematologic malignancies are particularly vulnerable to COVID-19 infections, and upon a pooled data analysis of 24 publications, there is evidence that they have suboptimal antibody responses to COVID-19 vaccination and boosters. To provide them the needed additional protection from CO...

Full description

Saved in:
Bibliographic Details
Published in:Blood cancer discovery 2021-11, Vol.2 (6), p.562-567
Main Authors: Ribas, Antoni, Dhodapkar, Madhav V, Campbell, Katie M, Davies, Faith E, Gore, Steven D, Levy, Ronald, Greenberger, Lee M
Format: Article
Language:English
Subjects:
Adult
COVID-19
COVID-19 Vaccines
Hematologic Neoplasms - therapy
Humans
Immunization, Secondary
SARS-CoV-2
Science in Society
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Patients with hematologic malignancies are particularly vulnerable to COVID-19 infections, and upon a pooled data analysis of 24 publications, there is evidence that they have suboptimal antibody responses to COVID-19 vaccination and boosters. To provide them the needed additional protection from COVID-19, it is imperative to achieve a 100% full immunization rate in health care workers and adult caretakers, and to foster research to test higher doses and repeated rounds of COVID-19 vaccines and the use of passive immune prophylaxis and therapy.
ISSN:2643-3230
2643-3249
DOI:10.1158/2643-3230.BCD-21-0166